(Press-News.org) CHAPEL HILL, NC--Boosting immune system T cells to effectively attack solid tumors, such as breast cancers, can be done by adding a small molecule to a treatment procedure called chimeric antigen receptor-T (CAR-T) cell therapy, according to a study by researchers at the UNC Lineberger Comprehensive Cancer Center. The boost helps recruit more immune cells into battle at the tumor site. The findings are published in the Journal of Experimental Medicine.
CAR-T immunotherapy, in which T cells are modified in the laboratory to express chimeric antigen receptors, CARs, that in turn target surface proteins on cancer cells, has been most effective in the treatment of patients with B-cell leukemia or lymphoma. But this new research, conducted in mouse models, points to the potential for using CAR-T therapy effectively against solid tumors as well.
"We know that CAR T cells are safe for patients with solid tumors but so far they have not been able to cause significant tumor regression in the overwhelming majority of people treated," said Jonathan S. Serody, MD, the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology and director of the Immunotherapy Program at UNC Lineberger. "Now we may have a new approach to make CAR T cells work in solid tumors, which we think could be a game-changer for therapies aimed at an appreciable number of cancers."
Serody is the paper's corresponding author and Nuo Xu, PhD, formerly a graduate student at UNC Lineberger and UNC School of Medicine, is the first author.
For CAR-T cell therapy to be effective, T cells infused back into patients have to be able to migrate to the site of a tumor. In treating patients with non-solid tumors, such as lymphomas, CAR T cells home in on bone marrow and other organs that make up the lymphatic system. But for solid tumors, such as breast cancer, that is usually not the case. Even if they do migrate to the tumor, they don't persist and expand well there due to the nature of the microenvironment surrounding such tumors, noted Serody.
So Serody and colleagues looked for ways to direct the lab-expanded cells toward the site of solid tumors. They focused on Th17 and Tc17 cells, which are known to have longer persistence in the micro-environment that surrounds a tumor, in part due to their better survival capabilities. To boost accumulation of Th17 and Tc17 cells near solid tumors, they turned to two small molecules that can activate an immune response: the stimulator of interferon genes (STING) agonists DMXAA and cGAMP.
DMXAA, which worked well in the investigator's mouse studies, has not provided benefit in human clinical trials as it does not activate human STING. The other STING agonist however, cGAMP, does activate human STING and is known to boost the human immune system. It also works well in mice.
In Serody's experiments, mice injected with cGAMP exhibited enhanced proliferation of T cells and those cells migrated to the tumor site. The end result was a significant decrease in tumor growth and enhanced survival.
"We hope to be able to study cGAMP in humans fairly soon," concluded Serody. "We will look to see if we can produce improvements in the treatment of head and neck cancers first, and if that proves promising, move into other forms of cancer by using CAR T cells generated by one of our colleagues here at UNC."
UNC Lineberger is one of a select few academic centers in the United States with the scientific, technical and clinical capabilities to develop and deliver CAR-T immunotherapy to patients. The cancer center currently has nine CAR-T clinical trials open and is developing new trials to treat a number of solid tumors, including ovarian and head and neck cancer. It also offers patients commercially available CAR-T therapies.
INFORMATION:
Authors and Disclosures
In addition to Serody and Xu, the paper's other authors are Alexander C. Robeson, PhD, Peishun Shou, PhD, Hemamalini Bommiasamy, PhD, Sonia J. Laurie, PhD, Caryn Willis, MS, Gianpietro Dotti, MD, and Benjamin Vincent, MD, UNC Lineberger and UNC School of Medicine; Douglas C. Palmer, PhD, National Cancer Institute; and Nicholas P. Restifo, MD, Lyell Immunophara, Inc., formerly of the National Cancer Institute.
This work was supported by grants from the National Cancer Institute (P50-CA058223) and the University Cancer Research Fund.
Serody has grant support from NCI, National Heart, Lung, and Blood Institute, Merck Inc., Glaxo Smith Kline, and Carisma Therapeutics. He receives consulting fees from PIQUE Therapeutics. Vincent discloses consulting fees and equity in GeneCentric Therapeutics. Dotti holds patents in the field of T cell engineering and has sponsored research agreements with Bluebird Bio, Cell Medica and Bellicum Pharmaceutical. Dotti also serves on the scientific advisory board of MolMed S.p.A and Bellicum Pharmaceutical. Serody, Restifo and Xu have filed for intellectual property protection for the use of STING agonists to enhance CAR-T cell therapy in solid tumors. No other disclosures were reported.
Producing clean water at a lower cost could be on the horizon after researchers from The University of Texas at Austin and Penn State solved a complex problem that has baffled scientists for decades, until now.
Desalination membranes remove salt and other chemicals from water, a process critical to the health of society, cleaning billions of gallons of water for agriculture, energy production and drinking. The idea seems simple -- push salty water through and clean water comes out the other side -- but it contains complex intricacies that scientists ...
Diamond is the hardest material in nature. But out of many expectations, it also has great potential as an excellent electronic material. A joint research team led by City University of Hong Kong (CityU) has demonstrated for the first time the large, uniform tensile elastic straining of microfabricated diamond arrays through the nanomechanical approach. Their findings have shown the potential of strained diamonds as prime candidates for advanced functional devices in microelectronics, photonics, and quantum information technologies.
The research was co-led by Dr Lu Yang, Associate Professor in the Department of Mechanical Engineering (MNE) at CityU and ...
AMES, Iowa - Nature has figured out how to make great membranes.
Biological membranes let the right stuff into cells while keeping the wrong stuff out. And, as researchers noted in a paper just published by the journal Science, they are remarkable and ideal for their job.
But they're not necessarily ideal for high-volume, industrial jobs such as pushing saltwater through a membrane to remove salt and make fresh water for drinking, irrigating crops, watering livestock or creating energy.
Can we learn from those high-performing biological membranes? Can we ...
Countries led by women have not fared significantly better in the COVID-19 pandemic than those led by men- it may be just our Western media bias that makes us think they have!
INFORMATION:
Article Title: "Gender in the time of COVID-19: Evaluating national leadership and COVID-19 fatalities"
Funding: The author(s) received no specific funding for this work.
Competing Interests: The authors have declared that no competing interests exist.
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244531
...
Very low birthweight infants are at a high risk for anemia and often need blood transfusions to survive. Some doctors use a higher level and some use a lower level of red blood cells to order a transfusion. A National Institutes of Health-funded study suggests that providing a higher threshold of red cells within clinically accepted limits (i.e., using a higher level of red blood cells when ordering a transfusion) offers no advantage in survival or reduction in neurological impairment over a lower threshold.
This large, multi-center randomized clinical trial was conducted ...
COLUMBUS, Ohio -- When using social media to nudge people toward safe and healthy behaviors, it's critical to make sure the words match the pictures, according to a new study.
After looking at social media posts, parents of young children were better able to recall safety messages such as how to put a baby safely to sleep when the images in the posts aligned with the messages in the text, the researchers found.
The study appears in the Journal of Health Communication.
"Many times, scientists and safety experts aren't involved in decisions about social media for health agencies and other organizations, and we end up seeing images that have nothing to do with the safety message ...
The scientists from St Petersburg University began to study the geology of Central Asia in the middle of the 20th century. Multi-year research and rich field experience have made it possible to create the world's leading school of thought in the geology of the Tien Shan at the University. At present, work continues with active collaboration with scientists throughout the world.
One of the recent discoveries of the international research team is the discovery of this specific rock assemblage that is characteristic of ...
BOSTON - Reports of possible allergic reactions to the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna, both recently approved for emergency use by the U.S. Food and Drug Administration (FDA), have raised public concern. A team of experts led by allergists at Massachusetts General Hospital (MGH) has now examined all relevant information to offer reassurance that the vaccines can be administered safely even to people with food or medication allergies. The group's review is published in the Journal of Allergy and Clinical Immunology: In Practice.
In response to accounts of potential allergic reactions in some people following COVID-19 ...
People with certain genetic conditions are likely to have significant symptoms of autism, even if they do not meet all diagnostic criteria, a study concludes.
Researchers at Cardiff University say their findings show clinical services need to adapt so that people diagnosed with autism-linked genetic conditions are not denied access to vital support and interventions.
Published in The American Journal of Psychiatry, the international study analysed data from 547 people who had been diagnosed with ...
ADELPHI, Md. -- Multi-domain operations, the Army's future operating concept, requires autonomous agents with learning components to operate alongside the warfighter. New Army research reduces the unpredictability of current training reinforcement learning policies so that they are more practically applicable to physical systems, especially ground robots.
These learning components will permit autonomous agents to reason and adapt to changing battlefield conditions, said Army researcher Dr. Alec Koppel from the U.S. Army Combat Capabilities Development Command, ...
